Why Is Belite Bio Stock Gaining Monday?
Belite Bio (BLTE) stock jumps 3% on positive Phase 3 DRAGON trial data for its Stargardt disease drug candidate tinlarebant.
Belite Bio tested a new medicine for an eye disease and got good results, which made people more interested in buying the stock. When a medicine test goes well, it can mean the company might make money in the future, so that's worth paying attention to.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.